STOCK TITAN

Rezolute prices offering for about $100M gross

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Rezolute, Inc. (RZLT) priced an underwritten offering of 22,040,976 common shares at $3.8700 each and pre-funded warrants for up to 3,800,000 shares at $3.8690 per warrant, with a $0.001 per-share exercise price. Gross proceeds are expected to be approximately $100 million; estimated net proceeds are approximately $93.5 million after underwriting discounts, commissions and offering expenses. Closing is expected on or about November 16, 2026, subject to customary closing conditions.

The company intends to use net proceeds together with existing cash and cash equivalents for ersodetug commercialization preparation, working capital and general corporate purposes. Warrant exercise is subject to beneficial-ownership limits of 4.99%, or up to 19.99% at a holder’s election; holders may change the limit on at least 61 days’ notice. Executive officers and directors agreed, subject to exceptions, not to dispose of their shares through 30 days after the final prospectus supplement without Morgan Stanley’s written consent.

Filing Explained

Rezolute has signed the underwriting agreement, with closing expected subject to customary conditions; if completed, the common-share issuance increases the share count and reduces existing holders’ percentage ownership, while warrant shares are issuable only on exercise and the warrants carry no votes.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Common shares offered 22,040,976 shares Underwritten offering priced November 13, 2026
Common share offering price $3.8700 per share Underwritten offering
Shares underlying pre-funded warrants Up to 3,800,000 shares Underwritten offering
Pre-funded warrant offering price $3.8690 per warrant Each warrant represents the right to purchase one share
Pre-funded warrant exercise price $0.001 per share Exercise price for each pre-funded warrant
Expected gross proceeds Approximately $100 million Before underwriting discounts, commissions and other offering expenses
Estimated net proceeds Approximately $93.5 million After underwriting discounts, commissions and offering expenses
Beneficial-ownership limit 4.99%, or up to 19.99% Pre-funded warrant exercise limit, subject to holder election
Pre-Funded Warrants financial
"pre-funded warrants to purchase up to 3,800,000 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
underwritten offering financial
"issuance and sale in an underwritten offering"
An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.
shelf registration statement regulatory
"offered and sold pursuant to a shelf registration statement"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
underwriting discounts and commissions financial
"after deducting the underwriting discounts and commissions"
Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.
beneficially owned financial
"shares of Common Stock beneficially owned by such holder"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
customary closing conditions financial
"subject to satisfaction of customary closing conditions"
"Customary closing conditions" are standard rules or checks that must be met before a business deal can be finalized, like making sure all paperwork is in order or that certain approvals are obtained. They matter because they help protect both parties, ensuring everything is in place and reducing the risk of surprises or problems after the deal is closed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares and pre-funded warrants is RZLT offering?

Rezolute priced 22,040,976 common shares and pre-funded warrants to purchase up to 3,800,000 shares. The common shares are priced at $3.8700 each, and each pre-funded warrant is priced at $3.8690 with a $0.001 per-share exercise price.

How much net proceeds does RZLT expect from the offering, and what will it use them for?

Rezolute estimates net proceeds of approximately $93.5 million after underwriting discounts, commissions and offering expenses. The company intends to use the proceeds, together with existing cash and cash equivalents, for ersodetug commercialization preparation, working capital and general corporate purposes.

What ownership limits apply to RZLT’s pre-funded warrants?

A holder generally may not exercise warrants if doing so would result in the holder and its affiliates exceeding 4.99% beneficial ownership or voting power; the holder may elect a limit of up to 19.99%. A holder may change the percentage on at least 61 days’ notice to the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001509261 0001509261 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 13, 2026

 

 

REZOLUTE, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

Nevada   001-39683   27-3440894

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

275 Shoreline Drive, Suite 500, Redwood City, CA 94065

(Address of Principal Executive Offices, and Zip Code)

 

650-206-4507

Registrant’s Telephone Number, Including Area Code

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share RZLT Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

Underwriting Agreement

 

On November 13, 2026, Rezolute, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed therein (the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) by the Company of (i) 22,040,976 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an offering price of $3.8700 per share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 3,800,000 shares of Common Stock at an offering price of $3.8690 per Pre-Funded Warrant, which represents the per share offering price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant.

 

The Shares and Pre-Funded Warrants in the Offering are being offered pursuant to a registration statement on Form S-3 (File No. 333-299867) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the “SEC”) on November 10, 2026 under the Securities Act of 1933, as amended (the “Securities Act”).

 

The closing of the Offering is expected to occur on or about November 16, 2026, subject to satisfaction of customary closing conditions. The estimated net proceeds of the Offering to the Company, after deducting the underwriting discounts and commissions and offering expenses payable by the Company, are approximately $93.5 million. The Company intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents, to fund ersodetug commercialization preparation and for working capital and general corporate purposes.

  

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, and other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Underwriting Agreement.

 

Subject to certain exceptions, the Company’s executive officers and directors have agreed not to sell or otherwise dispose of any of the shares of Common Stock held by them for a period beginning on the date of execution of the applicable lock-up agreements by each such executive officer and director and ending 30 days after the date of the final prospectus supplement filed with the SEC in connection with the Offering pursuant to Rule 424(b) under the Securities Act without first obtaining the written consent of Morgan Stanley.

 

 

 

 

The Pre-Funded Warrants offered in the Offering have an exercise price of $0.001 per share, which is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the shares of Common Stock and also upon any distributions for no consideration of assets to the Company's stockholders. Each Pre-Funded Warrant is exercisable at any time and from time to time after issuance. In the event of certain fundamental transactions, the holders of the Pre-Funded Warrants will be entitled to receive, upon exercise of the Pre-Funded Warrants, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such transaction. The Pre-Funded Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which holders of Common Stock are entitled. The Company may not effect the exercise of any Pre-Funded Warrants, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would result in: (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, up to 19.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of the Company’s securities beneficially owned by such holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, up to 19.99%) of the combined voting power of all of the Company’s securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants, which percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to the Company. The foregoing summary of the Pre-Funded Warrants does not purport to be complete and is subject to, and qualified in its entirety by, the form of Pre-Funded Warrant, which is filed herewith as Exhibit 4.1 and incorporated herein by reference.

 

The foregoing summary of the Underwriting Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the Underwriting Agreement, which is filed herewith as Exhibit 1.1 and incorporated herein by reference.

 

A copy of the opinion of Dorsey & Whitney LLP relating to the legality of the issuance and sale of the Shares and the Pre-Funded Warrants offered in the Offering, and shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants offered in the Offering, is attached as Exhibit 5.1 hereto and is incorporated by reference herein.

  

Item 7.01. Regulation FD Disclosure.

 

Pricing Press Release

 

On November 13, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached hereto as Exhibit 99.1.

 

The information in Item 7.01 of this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, and shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

 

 

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Description

 

1.1 Underwriting Agreement, dated as of November 13, 2026, by and between the Company and Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein
4.1 Form of Pre-Funded Warrant
5.1 Opinion of Dorsey & Whitney LLP
23.1 Consent of Dorsey & Whitney LLP (included in Exhibit 5.1)
99.1* Press Release, dated November 13, 2026
104 Cover Page Interactive Data File (formatted as inline XBRL)

 

* This exhibit is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.

 

Caution Concerning Forward-Looking Statements

 

This Current Report on Form 8-K may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements include statements about the closing of the Offering and the anticipated use of proceeds of the Offering. These forward-looking statements are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including the uncertainties related to market conditions, the satisfaction of customary closing conditions related to the Offering, and the completion of the Offering on the anticipated terms or at all. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2026, in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and in the Company’s other reports filed with the SEC. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  REZOLUTE, INC.
     
DATE: November 16, 2026 By: /s/ Nevan Charles Elam
    Nevan Charles Elam
    Chief Executive Officer

 

 

 

Exhibit 99.1

 

 

 

Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

 

Transaction led by Frazier Life Sciences with participation from new and existing funds

 

REDWOOD CITY, Calif., November 13, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced the pricing of an underwritten offering of 22,040,976 shares of its common stock at an offering price of $3.87 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,800,000 shares of common stock at an offering price of $3.869 per pre-funded warrant, which represents the per share offering price for the common stock, less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Rezolute from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $100 million. The offering is expected to close on or about November 16, 2026, subject to the satisfaction of customary closing conditions.

 

The Company intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, to fund ersodetug commercialization preparation, working capital and general corporate purposes.

 

The financing is being led by Frazier Life Sciences and includes participation from new and existing funds.

 

Morgan Stanley, Guggenheim Securities, and Cantor are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and Jones are acting as lead managers for the offering. Maxim Group LLC and Lake Street Capital Markets, LLC are acting as co-managers for the offering.

 

The securities in the registered offering are being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-299867), filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 5, 2026, and declared effective on November 10, 2026. A prospectus supplement and accompanying prospectus describing the terms of the registered offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone: 1-866-718-1649 or by email: prospectus@morganstanley.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, or by phone: 1-212-518-9544, or by email: GSEquityProspectusDelivery@guggenheimsecurities.com; or Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email: prospectus@cantor.com.

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

 

 

 

About Rezolute, Inc.

 

Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI.

 

Forward-Looking Statements

 

This release, like many written and oral communications presented by Rezolute and its authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to, Rezolute’s expectations regarding the anticipated use of proceeds and the completion of the offering. The Company’s ability to predict results or the actual effects of its plans or strategies is inherently uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include, among others, those related to market and other financial conditions, satisfaction of customary closing conditions related to the offering, and any other factors discussed in Rezolute’s filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.

 

Rezolute Contacts:

 

Christen Baglaneas

Rezolute, Inc.

1411 Broadway, 16th Floor

New York, NY 10018

cbaglaneas@rezolutebio.com

508-272-6717

 

Carrie McKim

Rezolute, Inc.

1411 Broadway, 16th Floor

New York, NY 10018

cmckim@rezolutebio.com

336-608-9706

 

 

 

Filing Exhibits & Attachments

7 documents

Keep reading